[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368269-105":59,"doc-detail-368269-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nab-paclitaxel-plus-capecitabine-as-a-first-line-regimen-for-advanced-biliary-tract-cancers-feasible-or-not-feasible","Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?","","A clinical trial evaluating nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers (BTCs) was presented in a Letter to the Editor context. The analysis reviews the evolution of systemic therapy recommended by National Comprehensive Cancer Network guidelines and summarizes prior development of nab-paclitaxel-based combination chemotherapy for advanced BTCs. The conclusion states that nab-paclitaxel plus capecitabine represents a promising first-line regimen for advanced BTC patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nab-paclitaxel-plus-capecitabine-as-a-first-line-regimen-for-advanced-biliary-tract-cancers-feasible-or-not-feasible/368269/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nab-paclitaxel-plus-capecitabine-as-a-first-line-regimen-for-advanced-biliary-tract-cancers-feasible-or-not-feasible/368269.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What treatment combination is evaluated for advanced biliary tract cancers?","Question",{"text":113,"@type":114},"Nab-paclitaxel plus capecitabine is evaluated as a first-line regimen for advanced biliary tract cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the letter position its main conclusion?",{"text":118,"@type":114},"It concludes that nab-paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs based on analysis of systemic therapy development.",{"name":120,"@type":111,"acceptedAnswer":121},"Which prior systemic therapies are discussed in the development overview?",{"text":122,"@type":114},"The letter discusses chemotherapy standards such as gemcitabine plus cisplatin, immune checkpoint inhibitor–based first-line approaches, and earlier clinical trial evidence including phase II results using nab-paclitaxel plus capecitabine.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368269,1790318617,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2025 March 14; 31(10): 100771  \nDOI: 10.3748/wjg.v31.i10.100771 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nLETTER TO THE EDITOR  \nNab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?  \nJian-Qiang Chen, Xiang Lan  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade C, Grade C, Grade C, Grade C, Grade D Novelty: Grade B, Grade B, Grade B, Grade C, Grade C  \nCreativity or Innovation: Grade B, Grade B, Grade C, Grade C, Grade D  \nScientific Significance: Grade B, Grade B, Grade C, Grade C, Grade C  \nP-Reviewer: Habib S; Kobayashi S; Xu M  \nReceived: August 26, 2024  \nRevised: January 10, 2025  \nAccepted: February 10, 2025  \nPublished online: March 14, 2025  \nProcessing time: 184 Days and 7.2 Hours  \nJian-Qiang Chen, Xiang Lan, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China  \nCorresponding author: Xiang Lan, MD, Doctor, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, [China.](China. lanxiangkeyan@163.com)[ lanxiangkeyan@163.com](China. lanxiangkeyan@163.com)  \nAbstract  \nA clinical trial of nab-paclitaxel plus capecitabine as a first-line treatment for advanced biliary tract cancers was conducted. We analyzed the development of systemic therapy recommended by the National Comprehensive Cancer Network guidelines and the development of nab-paclitaxel combination chemotherapy for advanced biliary tract cancers (BTCs) and concluded that nab-paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs.  \nKey Words: Nab-paclitaxel; Capecitabine; Biliary tract cancers; Systemic therapy; Firstline regimen  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \nCore Tip: We investigated the development and efficacy of systemic therapy for advanced biliary tract cancers (BTCs) and concluded that paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs.  \nCitation: Chen JQ, Lan X. Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? World J Gastroenterol 2025; 31(10): 100771  \nURL: [https://www.wjgnet.com/1007-9327/full/v31/i10/100771.htm](https://www.wjgnet.com/1007-9327/full/v31/i10/100771.htm)  \nDOI: [https://dx.doi.org/10.3748/wjg.v31.i10.100771](https://dx.doi.org/10.3748/wjg.v31.i10.100771)  \nTO THE EDITOR  \nBiliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder cancer, constitute approximately 4% of all malignant gastrointestinal tract neoplasms and are considered rare forms of tumors  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1 March 14, 2025  Volume 31  Issue 10   \nChen JQ et al. Nab-paclitaxel plus capecitabine for advanced BTCs  \n[1] . However, the prognosis of BTC is poor, with a 5-year overall survival (OS) of less than 20%[2] . Patients are usually diagnosed with advanced-stage BTCs when they have tumors, and systemic therapy has become the only choice for these patients.  \nMore than 10 years ago, the combination of chemotherapy with gemcitabine and cisplatin became the standard-of-care first-line therapy for advanced biliary tract cancer. Nevertheless, the median OS of patients receiving this doublet chemotherapy is still less than 1 year [3,4] . In recent years, immune checkpoint inhibitors, including durvalumab and pembrolizumab, have been proven effective in advanced BTCs. Chemotherapy inv","cbCaipsP9eVutH51","https://ap.wps.com/l/cbCaipsP9eVutH51","pdf",482698,"English","# Letter to the editor\n## Abstract and key conclusion\n## Development of systemic therapy for advanced BTCs","[{\"question\":\"What treatment combination is evaluated for advanced biliary tract cancers?\",\"answer\":\"Nab-paclitaxel plus capecitabine is evaluated as a first-line regimen for advanced biliary tract cancers.\"},{\"question\":\"How does the letter position its main conclusion?\",\"answer\":\"It concludes that nab-paclitaxel plus capecitabine is a promising first-line regimen for advanced BTCs based on analysis of systemic therapy development.\"},{\"question\":\"Which prior systemic therapies are discussed in the development overview?\",\"answer\":\"The letter discusses chemotherapy standards such as gemcitabine plus cisplatin, immune checkpoint inhibitor–based first-line approaches, and earlier clinical trial evidence including phase II results using nab-paclitaxel plus capecitabine.\"}]","Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? | PDF",1790175959,15]